2 not yet recruiting, 1 active not recruiting, 1 unknown. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 2, Unknown 1 |
| Phase 3 | 2 | Not yet recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Paclitaxel or Nab-Paclitaxel: new trials by email Literature Review of Paclitaxel or Nab-Paclitaxel trials Research Report on Paclitaxel or Nab-Paclitaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer HLX07, HLX07 placebo, Serplulimab - Squamous NSCLC | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 720 | 2026-03-01 | 2026-01-06 |
| Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma chemotherapy TP regimen combined with Toripalimab - Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Unknown | Fudan University | 42 | 2021-04-07 | 2022-01-18 |
| A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors MEDI5752, Pemetrexed, Carboplatin - Selected Advanced Solid Tumors | Phase 1 | Active not recruiting | MedImmune LLC | 400 | 2018-04-24 | 2026-08-21 |
Carcinoma, Non-Small-Cell Lung (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Neoplasms (1)
Shanghai Henlius Biotech (2) · Fudan University (1) · MedImmune LLC (1)
China (3) · Australia (1) · France (1) · Italy (1) · Netherlands (1) · Portugal (1) · South Korea (1) · Spain (1) · Taiwan (1) · United States (1)
Deepa Subramaniam, MD, MSc (1) · Xiayun He, M.D. (1) · Yu Wang, M.D. (1)
2018 (1), 2023 (1)